Renal function in patients with anemia and severe chronic heart failure: effects of iron medications
Abstract
Aim. To investigate the prevalence of anemia and renal dysfunction combination among patients with severe chronic heart failure (CHF), as well as the effects of intravenous (i/v) iron therapy.
Material and methods. In total, 42 patients (mean age 69,3+1,2 years) with Functional Class III-IV stable CHF (NYHA classification) were examined. Glomerular filtration rate (GFR) was calculated based on creatinine concentration (MDRD formula). Anemia was diagnosed by WHO criteria: hemoglobin (Hb) level <130 g/1 in men and <120 g/1 in women. Eleven patients were administered Venofer for 24 weeks. At baseline and after the treatment course, 6-minute walk test (6mw) was performed.
Results. Anemia was diagnosed in 17 (40,5%) patients, including 13 with iron deficiency. Chronic renal failure (CRF; GFR< 60 ml/min) was observed in 64,7 % of the participants. Clinical and laboratory parameters were compared in patients with cardiorenal syndrome (GFR<60 ml/min) with or without anemia. Significant negative correlation was observed between Hb and creatinine levels (p=-0,02), with positive correlation between hematocrit (Ht) and GFR levels (p=0,044). Intravenous iron therapy was associated with a significant increase in Hb (from 128,2+14,4 to 139,0+17,4 g/1; p=0,03), Ht (from 38,4+3,5 to 41,3+5,06; p=0,03), and physical stress tolerance (PST), according to 6mw test results.
Conclusion. The combination of cardiac pathology, renal dysfunction and iron-deficient anemia was typical of patients with severe CHF. Iron therapy was associated with significant increase in Hb, Ht, and PST levels, without any severe adverse effects.
About the Authors
M. A. Efremovtseva
Russian University of People’s Friendship. Moscow
Russian Federation
Russian Federation
T. A. Kasantseva
Russian University of People’s Friendship. Moscow
Russian Federation
Russian Federation
L. G. Aleksandriya
Russian University of People’s Friendship. Moscow
Russian Federation
Russian Federation
T. B. Dmitrova
Russian University of People’s Friendship. Moscow
Russian Federation
Russian Federation
References
1. Felker G.M., Leimberger J.D., Califf R.M., et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004; 10: 460-6.
2. Go A.S., Yang J., Ackerson L.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Out comes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113: 2713-23.
3. Knight E.L., Glynn R.J., Mclntyre K.M., et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies Of Left Ventricular Dysfunction (SOLVD). Am Heart J 1999; 138: 849-55.
4. Шутов A.M., Тармонова Л.Ю., Чернышева Е.В., Альберт MA. Кардиоренальный анемический синдром у больных пожилого возраста. Нефролдиал 2006; 8(4): 350-3.
5. Philipp S., Henrike О., Schink T., et al. Luft and Willenbrock R. The impact of anaemia and kidney function in congestive heart failure and preserved systolic function. Oxford J NDT 2005; 20(5): 915-9.
6. Keane W., Brenner B., de Zeeuw D., et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-507.
7. Canaud B., Mann J., Teatini U., et al. Оптимальное лечение нефрогенной анемии. Ж Анемия 2005; 1: 23-5.
8. Norman J.T., Clark I.M., Garcia P.L. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58(6): 2351-66.
9. Добронравов В.А. Анемия и хроническая болезнь почек. Ж Анемия 2005; 2: 3.
10. Ермоленко В.М., Хасабов Н.Н., Михайлова НА. Рекомендации по применению препаратов железа у больных с хронической почечной недостаточностью. Ж Анемия 2005; 2: 10-21.
11. Шило В.Ю., Денисов А.Ю., Хасабов Н.Н. Венофер влечении анемии у больных на программном гемодиализе. Ж Анемия 2005; 1: 13-21.
12. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl Med 1998; 339: 584-90.
13. Strippoli G.F., Manno C., Schena Fp., Craig J.C. Haemoglobin and haematocrit for the anaemia of chronic renal disease (Cochrane review). Cochran Database Syst Rev 2003; 1: CD003967.
14. Drъeke Т.В., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84.
15. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
Review
For citations:
Efremovtseva M.A., Kasantseva T.A., Aleksandriya L.G., Dmitrova T.B. Renal function in patients with anemia and severe chronic heart failure: effects of iron medications. Cardiovascular Therapy and Prevention. 2008;7(4):68-71. (In Russ.)
Views:
478
Email this article 
